NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced today that David Wambeke has joined the company as Chief Business Officer and concurrently purchased 1,000,000 shares of NeuroOne common stock, signaling strong conviction in the company's growth trajectory. The appointment comes as NeuroOne advances its drug delivery program and seeks to maximize the strategic value of its emerging platform.
Wambeke will lead NeuroOne's drug delivery program and work closely with the executive team to refine product requirements for preclinical and clinical-stage devices, expand relationships with key opinion leaders, and engage prospective pharmaceutical partners. He will also oversee investor relations and support strategic business development initiatives, including partnerships and other corporate transactions.
Dave Rosa, CEO of NeuroOne, highlighted Wambeke's rare combination of public company experience and capital markets expertise. "As we continue to execute on our strategy and expand awareness of NeuroOne's technology platform, we believe David will be instrumental in sharpening our messaging, deepening investor engagement, and advancing business development activities that support long-term value creation," Rosa said.
Wambeke most recently served as Chief Business Officer at DiaMedica Therapeutics, where he led the strategic expansion of the company's lead biologic into preeclampsia, overseeing a first-in-pregnancy Phase 2 clinical trial that delivered positive results. Prior to DiaMedica, he spent approximately 16 years at Craig-Hallum Capital Group in life sciences investment banking, advising public and private healthcare companies on equity financings, M&A, and strategic transactions. He began his career in the U.S. Army and was awarded the Purple Heart after being wounded in combat in Baghdad, Iraq.
"I'm excited to join NeuroOne at such a pivotal moment and to meaningfully align myself with shareholders through my investment," said Wambeke. "With four FDA 510(k)-cleared devices and a strategic partnership with Zimmer Biomet, NeuroOne has validated its platform technology and established a strong commercial foundation in epilepsy and trigeminal nerve applications. As the Company continues to scale commercialization across these cleared indications, I believe even greater opportunities lie ahead in basivertebral ablation, drug delivery, and spinal cord stimulation."
In conjunction with his appointment, Wambeke purchased 1,000,000 shares of NeuroOne's common stock at $0.6704 per share, the closing price on February 27, 2026. The net proceeds will support ongoing clinical and product development activities, as well as working capital and general corporate purposes. The shares were issued in a private placement exempt from registration under the Securities Act of 1933.
Additionally, NeuroOne granted Wambeke an inducement stock option to purchase 500,000 shares under the 2021 Inducement Plan, with an exercise price of $0.6704 per share. The option vests over four years, with 25% vesting on the first anniversary and the remainder quarterly thereafter. The grant was approved by the compensation committee and was a material inducement for Wambeke's employment.
NeuroOne markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. The company is also engaged in research and development for drug delivery and spinal cord stimulation programs. For more information, visit nmtc1.com.
The company's forward-looking statements involve risks and uncertainties, including those related to continued Nasdaq listing compliance, strategic partnerships, market acceptance, and capital requirements. Detailed risk factors are described in NeuroOne's filings with the Securities and Exchange Commission.
